Is Viking Therapeutics a Buy on the Dip? | The Motley Fool

5 days ago · All of this means that Viking is a compelling buy on the dip for growth investors who can tolerate some risk. Adria Cimino has no position in any of the stocks mentioned. The …

CouponFollow Extension

54%
OFF

Is Viking Therapeutics Stock A Buy On The Dip? | The Motley Fool

2 weeks from now

Jun 6, 2024 · Viking Therapeutics (VKTX-0.54%) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered …

fool.com

71%
OFF

Is Viking Therapeutics Stock A Buy? | The Motley Fool

2 weeks from now

Sep 29, 2024 · One of the current stars of the biotech world is Viking Therapeutics (VKTX-2.71%), and for good reason. The clinical-stage company is advancing to the later stages of …

fool.com

531%
OFF

Got $5,000? Viking Therapeutics Stock Just Got A Big New Green …

2 weeks from now

Nov 7, 2024 · Motley Fool Issues Rare “All In” Buy Alert. NASDAQ: VKTX Viking Therapeutics. Market Cap. $7B. ... With a gain of more than 531% over the last 12 months, shares of Viking …

fool.com

14%
OFF

Where Will Viking Therapeutics Be In 5 Years? | The Motley Fool

2 weeks from now

Oct 14, 2024 · Motley Fool Issues Rare “All In” Buy Alert. ... Five years ago, Viking Therapeutics (VKTX-9.14%) was an unknown, clinical-stage biotech. It hardly stood out in a sea of small …

fool.com

$1500
OFF

Better Biotech Stock To Buy With $1,500 Right Now: Viking …

2 weeks from now

Oct 13, 2024 · The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool recommends Novo Nordisk. ... Is Viking Therapeutics a Buy on the Dip? 4 …

fool.com

531%
OFF

Got $5,000? Viking Therapeutics Stock Just Got A Big New Green …

2 weeks from now

Nov 7, 2024 · With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to say the least. And as of early …

yahoo.com

FAQs about Is Viking Therapeutics a Buy on the Dip? | The Motley Fool Coupon?

Is Viking Therapeutics stock a buy?

Viking Therapeutics stock is jumping Thursday afternoon after the biotech company reported third quarter results that topped analyst expectations. Wall Street currently holds 13 Buy ratings on the name. Market Domination Co-Hosts Julie Hyman and Josh Lipton break down the details. ...

Should you buy Viking Therapeutics (vktx) in 2024?

Viking Therapeutics ( VKTX 4.71%) is an anomaly of sorts. Despite another underwhelming year for biotech stocks, the metabolic disease specialist has, so far, delivered a staggering 208% return on capital for shareholders in 2024. The reason? Investors have flocked to the biotech stock in response to its experimental weight loss therapy, VK2735. ...

Should you buy Viking Therapeutics & Summit Therapeutics?

Viking Therapeutics (VKTX -0.64%) and Summit Therapeutics (SMMT 7.85%) are both up-and-coming biotechs with no sales revenue, plenty of cash in the bank, big catalysts on the horizon, and pipeline strategies that could place them in major markets relatively soon. That makes them more appealing than most biotech companies out there. ...

Are billionaires buying Viking Therapeutics stock left and right?

Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead? Wall Street investment banks keep pounding the table on Viking Therapeutics(NASDAQ: VKTX) and its weight loss drug candidate. Predictions vary, but the average analyst who follows the stock thinks it can rise 98% from recent prices. ...

Is Viking Therapeutics a good weight loss company?

Viking Therapeutics (VKTX -3.76%) is a clinical-stage pharma company that's been eyeing the weight loss market for some time now. During its third-quarter earnings call a few weeks ago, Viking's management revealed some interesting information -- and if I were an executive at Lilly, I'd be listening closely. ...

Is Viking Therapeutics a good biotech company?

Viking Therapeutics has two exciting pipeline candidates. The biotech could deliver excellent returns in the next five years if these programs perform well. There are also some risks to consider for the company. We could be witnessing the birth of a major player in the biotech industry. ...